Arch Venture Partners X, Llc - Net Worth and Insider Trading

Arch Venture Partners X, Llc Net Worth

The estimated net worth of Arch Venture Partners X, Llc is at least $407 Million dollars as of 2024-11-05. Arch Venture Partners X, Llc is the 10% Owner of Neumora Therapeutics Inc and owns about 29,545,420 shares of Neumora Therapeutics Inc (NMRA) stock worth over $346 Million. Arch Venture Partners X, Llc is also the 10% Owner of Prime Medicine Inc and owns about 15,456,594 shares of Prime Medicine Inc (PRME) stock worth over $61 Million. Details can be seen in Arch Venture Partners X, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arch Venture Partners X, Llc has not made any transactions after 2024-02-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Arch Venture Partners X, Llc

To

Arch Venture Partners X, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Partners X, Llc owns 6 companies in total, including Sienna Biopharmaceuticals Inc (SNNAQ) , Erasca Inc (ERAS) , and Sana Biotechnology Inc (SANA) among others .

Click here to see the complete history of Arch Venture Partners X, Llc’s form 4 insider trades.

Insider Ownership Summary of Arch Venture Partners X, Llc

Ticker Comapny Transaction Date Type of Owner
SNNAQ Sienna Biopharmaceuticals Inc 2019-02-22 10 percent owner
ERAS Erasca Inc 2021-07-15 10 percent owner
SANA Sana Biotechnology Inc 2021-02-03 10 percent owner
LIMIT LIMIT 2021-06-16 10 percent owner
LIMIT LIMIT 2024-02-15 10 percent owner
LIMIT LIMIT 2023-09-19 10 percent owner

Arch Venture Partners X, Llc Latest Holdings Summary

Arch Venture Partners X, Llc currently owns a total of 2 stocks. Among these stocks, Arch Venture Partners X, Llc owns 29,545,420 shares of Neumora Therapeutics Inc (NMRA) as of September 19, 2023, with a value of $346 Million and a weighting of 84.98%. Arch Venture Partners X, Llc also owns 15,456,594 shares of Prime Medicine Inc (PRME) as of February 15, 2024, with a value of $61 Million and a weighting of 15.02%.

Latest Holdings of Arch Venture Partners X, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NMRA Neumora Therapeutics Inc 2023-09-19 29,545,420 11.72 346,272,322
PRME Prime Medicine Inc 2024-02-15 15,456,594 3.96 61,208,112

Holding Weightings of Arch Venture Partners X, Llc


Arch Venture Partners X, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Arch Venture Partners X, Llc has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 1,500,000 shares on September 19, 2023, which cost Arch Venture Partners X, Llc around $26 Million.

According to the SEC Form 4 filings, Arch Venture Partners X, Llc has made a total of 2 transactions in Prime Medicine Inc (PRME) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Prime Medicine Inc is the acquisition of 3,200,000 shares on February 15, 2024, which cost Arch Venture Partners X, Llc around $20 Million.

Insider Trading History of Arch Venture Partners X, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Arch Venture Partners X, Llc Trading Performance

GuruFocus tracks the stock performance after each of Arch Venture Partners X, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Partners X, Llc is 6.35%. GuruFocus also compares Arch Venture Partners X, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Partners X, Llc within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Arch Venture Partners X, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Arch Venture Partners X, Llc

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.35 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 0 LIMIT LIMIT LIMIT LIMIT LIMIT

Arch Venture Partners X, Llc Ownership Network

Ownership Network List of Arch Venture Partners X, Llc

No Data

Ownership Network Relation of Arch Venture Partners X, Llc

Insider Network Chart

Arch Venture Partners X, Llc Owned Company Details

What does Sienna Biopharmaceuticals Inc do?

Who are the key executives at Sienna Biopharmaceuticals Inc?

Arch Venture Partners X, Llc is the 10 percent owner of Sienna Biopharmaceuticals Inc. Other key executives at Sienna Biopharmaceuticals Inc include Chief Financial Officer Alexander Azoy , Chief Medical Officer Paul F. Lizzul , and director & President & CEO Iii Frederick Beddingfield .

Sienna Biopharmaceuticals Inc (SNNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sienna Biopharmaceuticals Inc (SNNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Sienna Biopharmaceuticals Inc Insider Transactions

No Available Data

Arch Venture Partners X, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Arch Venture Partners X, Llc. You might contact Arch Venture Partners X, Llc via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.